325 results about "Tumor target" patented technology

The invention relates to the technical field of tumor treatment, in particular to an intelligent decision-making system for tumor precise targeted medication based on individual mutation information, which comprises a data processing layer, a variation annotation and function prediction layer, a knowledge base integration layer and a scheme decision-making engine and report visualization module. According to the intelligent decision-making system for tumor precise targeted medication based on individual mutation information, a rule engine and a prediction model are combined, dynamic priority ranking is output, multi-model fusion decision making is achieved, and clinical scene deep adaptation is achieved by predicting primary and secondary drug resistance, calculating liver and kidney function adjusting dosage and generating a combined medication time sequence scheme; through an individualized drug delivery scheme, combination drug use optimization is achieved, a visual clinical report is generated, clinical executable operation is further strengthened, and through algorithm quantification, a dynamic knowledge graph, AI auxiliary decision making and a clinical operation closed loop, the next-generation technical research direction of a tumor precise drug use system can be represented.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

The invention discloses a 2.5 D dual-scale wavelet SAM-GAN liver tumor target region segmentation method, which comprises the following steps: establishing a segmentation model which is composed of a preprocessing module, a generation module and a discrimination module; an original image enters the preprocessing module and is subjected to neighborhood slice feature aggregation and anatomical perception to generate a 2.5 D image, the 2.5 D image is optimized and enhanced in the generation module and then input into the judgment module, and the judgment module evaluates the authenticity of the image output by the generation module and provides feedback training for the generation module. According to the method, the defects in the prior art can be overcome, the feature extraction capability on the liver tumor data set is improved, and the training stability and the model generalization capability are enhanced.

The present invention relates to combination therapies employing tumor targeted anti-CEA / CD3 bispecific antibodies and / or agents blocking PD-L1 / PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules that also target FAP, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention discloses iron oxide nanoparticles capable of responding to particle size change in a tumor microenvironment and a preparation method of the iron oxide nanoparticles, and belongs to the technical field of biomedical nano materials. The nano-particle comprises an iron oxide nano-crystal core with the particle size of 3-5nm and a tumor microenvironment response layer coating the surface of the iron oxide nano-crystal core. The response layer contains groups, such as disulfide bonds, enzyme digestion peptide fragments and the like, which can respond to acidic pH, high-concentration reduced glutathione or matrix metalloproteinase and other tumor characteristic stimuli to generate structural changes. In a tumor microenvironment, the hydration particle size of the nanoparticles can be directionally and controllably converted from 3-20 nm to 20-100 nm (or reversely). The preparation method mainly comprises two steps of preparing the core by a thermal decomposition method and modifying the surface response layer. The technical problems of insufficient tumor targeted enrichment capacity, limited imaging contrast and difficulty in balancing permeation and retention caused by fixed particle size of the existing iron oxide nanoparticles are solved, and the accuracy and efficiency of tumor diagnosis and treatment can be remarkably improved.

The invention belongs to the technical field of biomedical functional dyes and probes, and relates to a fluorescent probe, in particular to a cyclodextrin-based near-infrared fluorescent probe, which is a conjugate formed by coating a fluorescent molecule with cyclodextrin. According to the near-infrared fluorescent probe disclosed by the invention, cyclodextrin is nested on a carbon chain of a fluorescent molecule, so that the water solubility, histocompatibility and safety are improved, the fluorescence lifetime is prolonged, the light stability is improved, and rapid transmission and response of ureters, lymphatic vessels and lymph nodes in vivo are realized; the method can be used for NIR-I and NIR-II imaging; a near-infrared fluorescence probe with targeting property can be formed by marking various tumor targeting molecules, so that accurate targeting fluorescence imaging of different types of tumors such as urogenital tumors, head and neck cancers, breast cancers and cervical cancers and metastatic lymph nodes in NIR-I and NIR-II windows is realized, and the near-infrared fluorescence probe can be applied to fluorescence imaging navigation in clinical operations.

The invention relates to a tumor target volume segmentation method and device and a storage medium. The method comprises the following steps: acquiring a medical image containing a target tumor; segmenting the target tumor in a spatial dimension according to the medical image to obtain a plurality of first target volumes which are located in the target tumor and are not overlapped; grouping the plurality of first target volumes to obtain a plurality of target volume groups; wherein each target volume group comprises at least one first target volume, and the adjacent first target volumes in the plurality of first target volumes are located in different target volume groups. According to the tumor target volume segmentation method and device and the storage medium provided by the invention, continuous irradiation of adjacent areas can be avoided through differential irradiation of different target volume groups, so that accumulated damage to surrounding normal tissues is reduced.

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention relates to the technical field of image processing, in particular to a small intestine capsule endoscope target detection method which comprises the following steps: acquiring a small intestine capsule endoscope image; the method comprises the following steps: constructing an improved RT-DETR network, inserting an SCSA module between a backbone network and a neck network of the RT-DETR, and introducing a DFM module behind a three-branch Fusion module of the neck network; and the improved RT-DETR network adopts a Focaler-IoU loss function. According to the method, the problem that the accuracy of recognizing the tumor target by using the small intestine capsule endoscope image through RT-DETR needs to be further improved is solved.

The invention relates to the technical field of medical image processing and radiotherapy, in particular to an OVH-based breast cancer automatic radiotherapy plan design method and system. Constructing a historical database, and integrating the image data of the patient, the delineation structure of the target region and the organ at risk and the dose information; calculating an OVH index, and quantifying a spatial geometrical relationship between the breast cancer tumor target region and the key endangered organ; and extracting a target area external expansion distance Lx corresponding to the specific volume x of the organ in the OVH curve and a dose value Dx corresponding to the volume point in the dose-volume histogram. And constructing a function model between Lx and Dx through linear regression analysis. And for a new patient, the system calculates the Lx value of the organ of interest of the new patient, inputs the value into the linear model, and predicts the corresponding radiotherapy dose Dx. According to the method provided by the invention, intelligent aided design of the breast cancer radiotherapy plan can be realized, and a scientific and acceptable dose prediction basis is provided.

The invention belongs to the technical field of radiopharmaceuticals, and particularly relates to a GPC3 targeted polypeptide probe and application thereof. According to the polypeptide probe targeting GPC3, non-natural functional groups are introduced to modify polypeptide ligands so as to enhance affinity, radiolabeling is carried out, and the polypeptide probe is used for PET molecular imaging diagnosis. The polypeptide probe shows good tumor targeting in vivo, the uptake of tumor tissues is remarkably different from that of normal liver tissues, the background of the normal liver tissues is clear, and a powerful tool and a theoretical basis are provided for noninvasive precise diagnosis of GPC3 positive liver cancer.

The invention relates to a bone tumor ablation target region identification and real-time updating method. The method comprises the following steps: processing a multi-modal medical image acquired before an operation, performing information trust empowerment on a bone tumor area according to an image source type, structural definition, bone tissue shielding degree and spatial distribution complexity, and dividing the bone tumor area into a core target area, a semi-trusted marginal area and a dispute area; in the intraoperative ablation process, an ablation temperature change path, power response distribution and navigation position information are continuously monitored, and when it is detected that temperature response is sparse, a needle tip is static and energy motivates discontinuous feature combination in a semi-credible marginal area or a dispute area, target area offset warning logic is triggered; according to the bone tumor target region identification mechanism based on the multi-modal medical image trust empowerment, multi-dimensional information factors such as the image source type, the structure definition, the bone tissue shielding degree and the spatial distribution complexity can be considered at the same time.

The invention relates to the technical field of radiotherapy, and discloses a multi-modal image fusion guided chest tumor adaptive radiotherapy system. The system comprises an asynchronous bimodal sensing module, a spectrum preprocessing module, a parameter inversion module, a boundary construction module and a biomechanical calculation module. According to the method, the feedback voxel-level velocity field is utilized to execute Lagrange reverse warping on the high-energy projection with physical time delay, and motion artifacts are eliminated; and dynamically updating the Young modulus of the lung tissue mechanical model based on the inverted real-time electron density, and solving a full-field three-dimensional displacement field in combination with double boundary conditions of body surface flexibility and internal skeleton rigidity so as to reconstruct a tumor target region and generate a beam control instruction. According to the method, through closed-loop interaction of image physics and biomechanics, the problems of dual-energy imaging motion artifact interference and insufficient lung tissue fixed parameter modeling precision are solved, and accurate self-adaptive tracking of a tumor target region is realized.

The present application relates to the field of immunology, and particularly relates to a novel IL-15 fusion protein and application thereof. The present application provides an IL-15 transmembrane fusion protein, which is applied to NK cells or CAR-NK cells, can significantly enhance the tumor killing function of NK cells and CAR-NK cells, and can effectively promote the proliferation of NK cells and CAR-NK cells. It provides an important basis for developing NK cell products armored by the IL-15 transmembrane fusion protein, which are independent of any tumor target, thereby reducing the cycle and cost of CAR-NK development. Meanwhile, the present application respectively carries out function research in blood tumors expressing CD19 and solid tumors expressing CD276, and the results indicate the broad-spectrum application prospect of the structure in tumors.

The invention discloses an interactive lattice radiotherapy planning method and system based on a functional image, and relates to the technical field of radiotherapy, and the method comprises the steps: obtaining a radiotherapy positioning CT image of a patient and a functional metabolism image after the space registration with the radiotherapy positioning CT image; based on the radiotherapy positioning CT image and a preset safety boundary parameter, determining a candidate area of lattice layout in the tumor target area; for each candidate position in the candidate region, adaptively calculating lattice parameters for the position based on the corresponding SUV value of the position in the functional metabolism image; determining a final lattice center set from the candidate positions through an iterative screening algorithm on the basis of the calculated lattice parameters of the candidate positions and preset geometric constraints and biological constraints, and generating a lattice target region set on the basis of the final lattice centers and the lattice diameters corresponding to the final lattice centers; and outputting the lattice target region set for dose calculation of a radiotherapy planning system. Individualized dosage improvement really based on tumor internal heterogeneity is achieved.

The invention provides a magnetic resonance guided charged particle beam radiotherapy device and an electromagnetic navigation parameter debugging method for target coordinates, and belongs to the technical field of radiotherapy devices. The system comprises a charged particle beam electromagnetic navigation device which comprises multiple stages of electromagnetic navigation coils, charged particle beams sequentially pass through the multiple stages of electromagnetic navigation coils, and parallel charged particle beams consistent with a magnetic resonance main magnetic field in direction are generated; the MR imaging device comprises an MR main magnetic field coil upper group and an MR main magnetic field coil lower group, and an imaging treatment area is formed between the MR main magnetic field coil upper group and the MR main magnetic field coil lower group. The electromagnetic navigation parameter debugging method comprises the steps of constructing a target cost function, optimizing electromagnetic navigation parameters based on an optimization algorithm without gradient information, and determining and outputting optimal navigation parameters. According to the invention, the charged particle beam parallel to the MR main magnetic field can be generated, the influence of Lorentz force on the charged particle beam is greatly reduced, the difficulty of positioning a tumor target region by the charged particle beam under the guidance of MR can be reduced, and the treatment accuracy is improved.

The application provides a tumor target area pose real-time tracking and prediction method and system, equipment and a medium. The abdominal respiration monitoring device of the system is used for detecting abdominal respiration deformation. The multi-channel array flexible acquisition sensor has deformability and is used for detecting back muscle electric signals and pressure change signals. The body surface information acquisition device is used for acquiring human chest and abdomen point cloud data. The main controller is used for processing data collected by the abdominal respiration monitoring device, the multi-channel array flexible acquisition sensor and the body surface information acquisition device, and obtaining a predicted position of a moving tumor target area. The application adopts back pressure muscle electric information and abdominal respiration deformation information and binocular vision information respiration movement evaluation, constructs a mapping relationship from external movement to internal tumor movement through external multi-mode data and 4D-CT information, combines a big data model, and realizes internal tumor pose prediction and evaluation.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

The application discloses a rare earth nanoparticle-organic photosensitizer composite material and application thereof. By introducing rare earth doped nanoparticles as an energy conversion medium, direct activation of excited triplet states of an organic photosensitizer and sensitized production of singlet oxygen under excitation of radionuclides (e.g., 64Cu, 67Cu, 90Y, 111In, 177Lu, etc.) are realized. 18 F、 99m Tc、 177 Lu, etc.) excitation, the rare earth doped nanoparticles respond to CL and the rare earth ions reach an excited state after various high-energy radiation. Subsequently, through an interface energy transfer process, the excited state energy of the rare earth ions is directly transferred to the excited triplet state of the organic photosensitizer, and then singlet oxygen is generated, realizing tumor cell killing. The nanocomposite material is surface modified to load iRGD peptides to realize in vivo tumor targeting. 18 F-FDG (fluorodeoxyglucose) can realize tumor targeting through abnormal glucose uptake of tumors. The combination of the two realizes double targeting of in vivo tumors, and enhances the anti-tumor efficacy and safety.

The invention provides a bacterial outer membrane vesicle drug carrier with a targeting effect and preparation, and relates to the technical field of biological medicines.The bacterial outer membrane vesicle protein ClyA derived from an escherichia coli W3110 strain is combined with iRGD protein capable of being combined with an integrin receptor alpha v beta 3, a ClyA-iRGD-pGEX-6P-1 recombinant plasmid for expressing ClyA-iRGD fusion protein is constructed, and the ClyA-iRGD-pGEX-6P-1 recombinant plasmid is used for preparing the bacterial outer membrane vesicle drug carrier with the targeting effect. By endogenous expression of the plasmid in W3110 escherichia coli, the C-iRGD-OMVs which has a tumor targeting effect and shows ClyA-iRGD fusion protein on the surface is prepared. The C-iRGD-OMVs shows efficient targeting binding capacity to MCF-7 breast cancer cells, overcomes the defect that iRGD single peptide is prone to aggregation and crystallization, has the potential of loading drugs, lays a foundation for the C-iRGD-OMVs serving as a targeting carrier for delivering breast cancer treatment drugs, and is expected to be further developed into a targeting treatment preparation for breast cancer.

The invention belongs to the technical field of biological medicine, and particularly provides application of a PLA1A gene / protein as an anti-tumor target. The key effect of the PLA1A gene / protein in promoting chemotherapy drug resistance is disclosed for the first time, and a new mechanism that the PLA1A gene / protein affects chemotherapy sensitivity by regulating a tumor microenvironment (especially macrophage polarization) is deeply clarified. Researches prove that knockdown of the PLA1A gene or inhibition of the protein activity of the PLA1A gene can significantly enhance the sensitivity of tumor cells to chemotherapeutic drugs (such as oxaliplatin), so that the therapeutic effect is improved, and the sensitization provides a new strategy for overcoming tumor chemotherapeutic drug resistance. In animal model experiments, knockdown of the PLA1A is combined with oxaliplatin for treatment, so that growth of mouse transplanted tumors and liver metastases is remarkably inhibited, the survival time of tumor-bearing mice is prolonged, and it is indicated that the PLA1A has important clinical application value and wide application prospects as an anti-tumor target.

The present invention provides a method for preparing and using a CD70-specific diagnostic-integrated molecular imaging probe, which comprises a tumor targeting group and a radionuclide, the tumor targeting group being selected from a CD70-specific nanobody or a CD70-specific nanobody fusion protein, the CD70-specific nanobody being B3 or B6 having the amino acid sequences set forth in SEQ ID NO. 1 and SEQ ID NO. 3, and the CD70-specific nanobody fusion protein being ABDB3 or ABDB6 having the amino acid sequences set forth in SEQ ID NO. 5 and SEQ ID NO. 7. The present invention achieves noninvasive visualization of human CD70 molecule expression and realizes noninvasive diagnosis of renal cell carcinoma. This probe has the advantages of simple preparation, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical translation.

Therapeutic polypeptides, compositions thereof and methods of use thereof for activating NK cells and treating tumors are provided. The therapeutic polypeptides can include a first domain for binding NKG2D and a second domain for binding a tumor target.

The invention belongs to the technical field of biological medicines, and particularly discloses a pH and ultrasound double-response type oncolytic microorganism as well as a preparation method and application thereof. On the basis of a tumor targeting platform, a mild thermal response gene loop expression GM-CSF and a surface-coated oncolytic microbial system are integrated, chemotherapeutic drugs are released in a tumor core area, and immunogenic cell death is induced. A thermal response loop is accurately activated through low-intensity focused ultrasound, and engineering bacteria are promoted to express GM-CSF and secrete a large amount of mannose modified OMVs. Due to the nanometer size and mannose targeting of the OMVs, the OMVs are efficiently enriched in lymph nodes, the OMVs are reprogrammed into an immune activation state from an immune tolerance state, and the OMVs and ICD cooperate to promote dendritic cell maturation, tumor antigen presentation and activation of tumor killer T cells, so that a remarkable and powerful treatment effect is achieved in various tumor models, and the application prospect is wide. A new strategy is provided for remodeling the lymph node immune microenvironment and enhancing the anti-tumor immune response.

Relates to a lipid composition with targeting property, the lipid composition comprises an active component, a lipid carrier and a targeting component, and the components of the lipid carrier comprise a positively charged component and phospholipid. An active component is entrapped in a lipid carrier containing a component with positive charges, so that the surface of the lipid carrier has positive charges, then the lipid carrier and a targeting component with negative charges are mixed, and the targeting component is adsorbed on the surface of the drug-loaded lipid carrier with positive charges through an electrostatic adsorption effect, so that the drug-loaded lipid carrier which is high in transfection efficiency and good in transfection effect is prepared. The present invention relates to a lipid composition having a targeting property and a high targeting property. The invention relates to a lipid nanoparticle delivery system with high biological activity, tumor targeting property and good safety. The lipid nanoparticle delivery system comprises an active component, cationic lipid, ionizable lipid and neutral phospholipid. The active component is entrapped in the lipid nanoparticle containing the cationic lipid, the ionizable lipid and the neutral phospholipid, and when the molar ratio of the cationic lipid to the ionizable lipid is in a specific range, the lipid nanoparticle has higher biological activity, tumor targeting property and good safety.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

Provided is a bispecific antibody targeting CD3 and a tumor target and a use of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region, and an Fc portion; the Fc portion comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein or fragment thereof of a first molecule, the binding protein or fragment thereof of the first molecule is linked to the N-terminal of the scFv fragment, and the C-terminal of the scFv fragment is linked to the N-terminal of the first Fc peptide fragment; the second antigen binding region comprises a binding protein or fragment thereof of a second molecule; and the first molecule and the second molecule are the identical, and the scFv fragment has CD3 binding activity.

Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment.In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a controlled drug-to-antibody ratio (DAR) to a target site.